From Pharma to CRO entrepreneur

In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest.

The conversation covers:

• Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure
• The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business
• How a major strategic partnership transformed the company’s trajectory and why Jean sees partnerships as a competitive weapon
• Riding the tailwind of the FDA’s move away from animal testing and offering something game-changing in the CMC and GMP space
• The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation

Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application.

Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise.

 

Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We’d also appreciate a positive rating!